2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6014 Higher-dose anti-CD25, methotrexate-free prophylaxis is associated with reduced acute GVHD and improved GRFS after haploidentical transplantation

Qianlin Liu, N/A, Wei Shi2, Linghui Xia3, Hu Yu, MD4
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Introduction: Optimizing graft-versus-host disease (GVHD) prophylaxis without compromising immune recovery remains a major challenge after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). More intensive blockade of the interleukin-2 receptor may suppress early alloreactivity, but its clinical and immunologic consequences are uncertain. We prospectively compared 2 anti-CD25–based prophylactic strategies after haplo-HSCT.

Methods: Patients with hematologic malignancies undergoing haplo-HSCT at a single center between May 2022 and January 2025 were enrolled in this prospective, nonrandomized comparative cohort. All patients received rabbit anti-thymocyte globulin (rATG), tacrolimus, and mycophenolate mofetil without post-transplant cyclophosphamide. The lower-dose group received anti-CD25 25 mg on days 0 and +4 plus short-course methotrexate (MTX), whereas the higher-dose group received 50 mg on days 0 and +4 without MTX. Treatment allocation was primarily determined by patient preference after physician counseling. The primary endpoint was acute GVHD; secondary endpoints included chronic GVHD, relapse, non-relapse mortality (NRM), overall survival (OS), disease-free survival (DFS), and GVHD-free, relapse-free survival (GRFS). Inverse probability of treatment weighting (IPTW) based on 20 prespecified covariates, including cumulative rATG dose, was followed by doubly robust weighted Cox and Fine–Gray models. Immune reconstitution was evaluated in a prespecified exploratory subcohort using longitudinal mixed-effects models and competing-risk analyses with death before recovery as a competing event.

Results: Among 276 patients, 149 received the lower-dose/MTX-containing strategy and 127 received the higher-dose/MTX-free strategy. Median follow-up was 28.4 months (95% CI, 24.8–35.5). After IPTW, the higher-dose strategy was associated with lower 100-day incidences of grade II–IV acute GVHD (15.0% vs 29.5%; adjusted subdistribution hazard ratio [aSHR], 0.45; 95% CI, 0.25–0.84; P=0.011) and grade III–IV acute GVHD (7.9% vs 17.5%; aSHR, 0.39; 95% CI, 0.18–0.88; P=0.022). GRFS was also improved, with 1- and 2-year estimates of 68.9% and 59.1% versus 56.2% and 50.3%, respectively (adjusted hazard ratio, 0.59; 95% CI, 0.43–0.83; P=0.002). Chronic GVHD, OS, DFS, relapse, and NRM did not differ significantly. Additional adjustment for transplantation year did not materially alter the treatment-effect estimates. Bloodstream infection was less frequent with the higher-dose strategy (3.1% vs 12.8%; IPTW-adjusted P=0.014), whereas cytomegalovirus and Epstein–Barr virus viraemia and pneumonia were comparable after weighting. Among 177 patients with longitudinal immune monitoring, day +30 CD4+ T-cell counts were lower in the higher-dose group (median, 70.4/μL vs 279.2/μL; IPTW-adjusted P=0.036), but were comparable from day +60 through day +540. No significant treatment-by-time interactions or between-group differences in sustained recovery of CD3+, CD4+, CD8+, CD19+, or natural killer cells were observed.

Conclusions: In this prospective nonrandomized cohort, a higher-dose anti-CD25, MTX-free prophylactic strategy was associated with substantially lower incidences of grade II–IV and grade III–IV acute GVHD and superior GRFS, without significant differences in relapse, NRM, OS, or DFS. Although CD4? T-cell counts were transiently lower at day +30, subsequent immune reconstitution was comparable between groups. These findings provide a rationale for multicenter randomized evaluation of this prophylactic strategy. Trial registration: ChiCTR2200060184.
Qianlin Liu, N/A: No relevant conflicts of interest to declare.